tbuckley/cabot-search huggingface dataset:
P2.06-006 Phase I/II Dose Escalation Study of L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Authors: Rodryg Ramlau, Dariusz Kowalski, Cezary Szczylik, Aleksandra Szczęsna, Elzbieta Wiatr, Steve Demas, Heman Chao, Kazimierz Roszkowski-Sliz
Journal: Journal of Thoracic Oncology (2017)
OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results
Authors: Kazuhiko Nakagawa, Luis Paz-Ares, Santiago Ponce, Jesus Corral, Oscar Vidal, Ernest Nadal, Katsuyuki Kiura, Jingyi Liu, Shuang He, Joseph Treat, Rita Dalal, Pablo Lee, Martin Reck
Journal: Journal of Thoracic Oncology (2017)
BH3 Mimetic Augments the Induction of Apoptosis by INNO-406, a Novel Bcr-Abl/Lyn Inhibitor, in Bcr-Abl+ Leukemic Cells.
Authors: Junya Kuroda, Shinya Kimura, Andreas Strasser, Michael Andreeff, Eishi Ashihara, Yoko Tabe, Masafumi Taniwaki, Taira Maekawa
Journal: Blood (2006)
Epinephrine-Induced Constriction of the Persistent Ductus Arteriosus and its Relation to Distensibility
Authors: Hideshi Tomita, Shigeto Fuse, Kinnya Hatakeyama, Shunzo Chiba
Journal: Circulation (1998)

The aim of this study was to investigate whether distensibility of the persistent ductus arteriosus (PDA) might predict its potential for vasoconstriction. Epinephrine-induced constriction and stretching were investigated in 10 patients with PDA. Age, sex, ductus type, its minimal diameter, its stretched minimal diameter, and its stretch index were compared between epinephrine responders and non-responders. Age, sex, weight or the configuration or size of the PDA did not predict stretchability. The stretch index was significantly greater in responders (1.7-2.0, 1.8+/-0.1) than in non-responders (1.3-1.7, 1.4+/-0.2, p<0.01). Stretching of the PDA may depend on the elasticity of the vascular wall, which in turn is determined by preservation of vascular smooth muscle.
Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.
Authors: Alessandro M. Gianni, Carmelo Carlo-Stella, Anna Guidetti, Michael Hallek, Carmen Schweighofer, Clemens Wendtner, Michele Ghielmini, Erica Lerch, Sabine Sperka, Douglas Greene, Oliver Krieter, Faith Nathan, Michael Petrone
Journal: Blood (2006)
Array-Based Karyotyping and Genotyping Demonstrates a Non Random Selection of Allelic Variants of Genes in Clones with 5q31 Deletion Mutants.
Authors: Lukasz P Gondek, Hemant Ishwaran, Andrew Jeffrey Dunbar, Christine L. O’Keefe, Michael A McDevitt, Denise Batista, Mikkael A. Sekeres, Ghulam J Mufti, Jaroslaw Maciejewski
Journal: Blood (2008)
Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.
Authors: Bertram Glass, Justin Hasenkamp, Peter Dreger, Martin Gramatzki, Joerg Schubert, Gerald G. Wulf, Maike Nickelsen, Lorenz H. Truemper, Norbert Schmitz
Journal: Blood (2007)
Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment
Authors: Sanjay Basu, Jeremy B. Sussman, Rod A. Hayward
Journal: Annals of Internal Medicine (2017)

Two recent randomized trials produced discordant results when testing the benefits and harms of treatment to reduce blood pressure (BP) in patients with cardiovascular disease (CVD).To perform a theoretical modeling study to identify whether large, clinically important differences in benefit and harm among patients (heterogeneous treatment effects [HTEs]) can be hidden in, and explain discordant results between, treat-to-target BP trials.Microsimulation.Results of 2 trials comparing standard (systolic BP target <140 mm Hg) with intensive (systolic BP target <120 mm Hg) BP treatment and data from the National Health and Nutrition Examination Survey (2013 to 2014).U.S. adults.5 years.Societal.BP treatment.CVD events and mortality.Clinically important HTEs could explain differences in outcomes between 2 trials of intensive BP treatment, particularly diminishing benefit with each additional BP agent (for example, adding a second agent reduces CVD risk [hazard ratio, 0.61], but adding a fourth agent to a third has no benefit) and increasing harm at low diastolic BP.Conventional treat-to-target trial designs had poor (<5%) statistical power to detect the HTEs, despite large samples (n > 20 000), and produced biased effect estimates. In contrast, a trial with sequential randomization to more intensive therapy achieved greater than 80% power and unbiased HTE estimates, despite small samples (n = 3500).The HTEs as a function of the number of BP agents only were explored. Simulated aggregate data from the trials were used as model inputs because individual-participant data were not available.Clinically important heterogeneity in intensive BP treatment effects remains undetectable in conventional trial designs but can be detected in sequential randomization trial designs.National Institutes of Health and U.S. Department of Veterans Affairs.
P1.05-015 Genomic Characterization of Non-Small Cell Lung Cancer in an Australian Population
Authors: Brielle Parris, Darryl Irwin, Marissa Daniels, Louise Franz, Felicia Goh, Linda Passmore, Elizabeth Mccaul, Deborah Courtney, Rayleen Bowman, Ian Yang, Kwun Fong
Journal: Journal of Thoracic Oncology (2017)
P221 Comparing the perception of feed-back mechanism of the breezhaler® device with the ellipta® device in patients with chronic obstructive pulmonary disease (COPD): the advantage study
Authors: P Altman, MA Bergna, GR Garcia, K Kostikas, T Guerin, AV Pino, J Whiteford
Journal: Thorax (2016)

<h3>Background and aims</h3> Patient preference and satisfaction with inhalers are important factors that may impact adherence to treatment and hence its outcome.<sup>1</sup> The ADVANTAGE study compared the Breezhaler® and the Ellipta® inhalers for patient perception of feedback mechanism and the comfort of the mouth piece, in COPD patients, naïve to dry powder inhaler use. <h3>Methods</h3> This open-label cross-over study randomised (1:1) patients (≥40 years) with COPD [all severities as per GOLD 2014] and smoking history of ≥10 pack-years to use both the Breezhaler® and Ellipta® devices in differing sequences with a separation of ≥5 minutes between devices. After inhalation, patients completed a questionnaire<sup>2</sup> containing 4 questions that captured patients’ perception of the feedback mechanism (mean of first three questions) and comfort of the mouth piece (fourth question). Questions were answered on a scale of 1 (lower preference) to 5 (higher preference), a Wilcoxon signed rank test was performed to test the difference between devices at a 2-sided 2.5% level of significance for both endpoints. Safety assessments included adverse events, physical examination, vital signs, height and weight. <h3>Results</h3> One hundred patients (64 men and 36 women) with a mean (SD) age of 65.2 (9.07) years were randomised to inhale sequentially through both devices. Thirty two patients were current smokers and had a mean (SD) duration of COPD for 6.1 (4.82) years. Overall, patients perceived that the Breezhaler® inhaler offered greater confidence of dose delivery and better comfort of the mouth piece (mean (SD) score 4.3 (0.70) and 4.3 (0.82); respectively) vs. the Ellipta® inhaler [mean (SD) score 3.6 (1.05) and 3.9 (0.84); respectively] (Figure). No safety signals were identified during the study. <h3>Conclusions</h3> In this study, COPD patients had greater confidence of receiving full dose with the Breezhaler® device and better comfort with the mouth piece compared with the Ellipta® device. <h3>References</h3> Anderson PJ. <i>Eur Respir Rev</i> 2005;<b>14</b>(96):109–116. Altman P, <i>et al</i>. <i>Prim Care Respir Med</i> 2016;<b>26</b>:CR052.
P2.01-085 Epigenetic Profile of Oligoprogressive versus Widespread Non-Small Cell Lung Cancer Patients
Authors: Carolina Gabay, María Juárez Rusjan, Gonzálo Recondo (H), Valeria Denninghoff, Martín Kransnapolsky, Liliana Giménez, Gonzalo Recondo, Luis Thompson, Monica Castro
Journal: Journal of Thoracic Oncology (2017)
A20 Tumor Suppressor Deletion and BCL6 Oncogene Activation Cooperate In Deregulating B Cell Differentiation In Vivo
Authors: Jonathan Mandelbaum, Qiong Shen, Hongyan Tang, Tongwei Mo, Barbara Malynn, Averil Ma, Riccardo Dalla-Favera, Laura Pasqualucci
Journal: Blood (2010)
Three Dimensional Speckle Tracking Echocardiography (3D-STE) for Early Detection of Subtle Myocardial Deformation Dysfunction in Thalassemic Patients
Authors: Hala Mounir Mohamed Moustafa Agha, Antoine AbdelMassih, Mohamed Youssef Abd El Rahman, Ornella Milanesi,, Biagio Castaldi, Giulia Geranio, Ludovica Frizziero, Giuseppe Basso, Maria Caterina Putti, Ahmed Essam, Reem Esmail, Ghada El-Kamah, Mona Hamdy, Heba El Baz, Noha El Behary, Carol Hanna, Hassan El Tagy, Mary Atef Mishriky, Mirna Mamdouh, Hossam Khalifa, Soheir Adam
Journal: Blood (2015)
OA20.07 HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status
Authors: Haiying Cheng, Murali Janakiram, Alain Borczuk, Juan Lin, Wanglong Qiu, Huijie Liu, Jordan Chinai, Balazs Halmos, Roman Perez-Soler, Xingxing Zang
Journal: Journal of Thoracic Oncology (2017)
P8 Negative pleural biopsies – do we need early follow up and imaging?
Authors: S Leyakathali Khan, B Ganaie, M Haris, M Munavvar
Journal: Thorax (2016)

<h3>Background</h3> Primary pleural or secondary malignancy is a common cause of pleural effusion. The incidence is about 200000 cases per year. Pleural biopsy remains gold standard investigation of choice. Those with negative biopsies are either discharged or have follow up depending on the multidisciplinary team decision. <h3>Objective</h3> To review the outcome of all patients with negative pleural biopsy including any follow up imaging for up to two years. <h3>Methods</h3> Retrospective analysis of 162 consecutive patients who underwent video-assisted thoracoscopic surgery (VATS) (100) and local anaesthetic thoracoscopy (62) between January 2011 and December 2012 across two large UK tertiary referral centres. Patients referred from peripheral centres were excluded. <h3>Results</h3> Of the 162 patients, male:female ratio was 109/53; average age was 69. Pleural biopsy histology was malignant in 63% (100); mesothelioma 43%, lung cancer 35%, extra pulmonary 22%. Granulomatous inflammation 6% (9). Benign 31% (53); chronic inflammation 28, fibrosis/thickening 8, reactive 13 and others 4. See Table 1. Of the 53 benign, 11 (21%) developed malignancy before 2 years. 6 (55%) required repeat biopsy. Patients alive at the end of 2 years – 1 Malignant and 26 benign of the 53. Imaging performed during 2 years follow up at 6, 12, and 24 months: plain chest radiograph 22 (42%), 12 (23%), 13 (25%) and CT scan was done at 5 (9%), 8 (16%), 2 (4%) respectively. <h3>Conclusion</h3> Our data suggests that 21% of patients were diagnosed as malignant within 2 years of initial negative biopsy, which is higher than expected.<sup>1</sup> There is a need for early follow up and imaging in patients with negative pleural biopsy. Further studies are required to establish the follow up interval and imaging modality. <h3>Reference</h3> Janssen J, Ramlal S, Mravunac M. The long-term follow up of exudative pleural effusion after nondiagnostic thoracoscopy. <i>J Bronchol</i> 2004;<b>11</b>(3):169–174.
A High Resolution Epigenomic Map of Myelofibrosis Reveals Multiple Chromosomal Deletions and Amplifications Accompanied by a High Level of Functionally Important Methylation.
Authors: Joanna Opalinska, Davendra Sohal, Simrit Parmar, Li Zhou, Andrew Yeatts, Perry Pahanish, Iris Isulfi, Kenny Ye, Maria Figueroa, Ari Melnick, John Greally, Amit Verma
Journal: Blood (2006)
P1.08-075 Salvage Surgery for Stage IV Non-Small Cell Lung Cancer
Authors: Hideaki Kojima, Shoko Hayashi, Kiyomichi Mizuno, Yoshiyuki Yasuura, Reiko Shimizu, Hiroyuki Kayata, Shoji Takahashi, Mitsuhiro Isaka, Toshiaki Takahashi, Yasuhisa Ohde
Journal: Journal of Thoracic Oncology (2017)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
Authors: Matthew Hellmann, Scott Antonia, Santiago Ponce, Patrick Ott, Emiliano Calvo, Matthew Taylor, Neal Ready, Christine Hann, Filippo De Braud, Joseph Paul Eder, Dirk Jäger, Paolo Ascierto, Leora Horn, Asim Amin, Jeffry Evans, Victor Moreno, Akin Atmaca, Rathi Pillai, Jaishree Bhosle, Petri Bono, Noemi Reguart, Jeffrey Schneider, Peter Brossart, Jennifer Diamond, Padmanee Sharma, Ulrik Lassen, Chen-Sheng Lin, Marina Tschaika, Giovanni Selvaggi, David Spigel
Journal: Journal of Thoracic Oncology (2017)
P2.05-035 Interim Analysis of the Phase II Trial Dose Risk Adapted FFF Using SBRT in Stage I NSCLC and Lung Metastases (NCT01823003)
Authors: Arturo Navarro-Martin, Ma Dolores Arnaiz, Francisco Pino, Ricard Ramos, Susana Padrones, Ernest Nadal, Valentin Navarro, Margarita Garcia, Jose Luis Vercher, Ferran Guedea
Journal: Journal of Thoracic Oncology (2017)
P1.08-029 Surgical Experience of Primary Salivary Gland Tumors of Lung: Experience from Tertiary Care Cancer Center in North India
Authors: Ashish Jakhetiya, Pankaj Garg, Surayanarayana Deo, Nootan Shukla, Durgatosh Pandey, Mukurdipi Ray, Prabhat Malik, Deepali Jain, Sunil Kumar
Journal: Journal of Thoracic Oncology (2017)
P1.06-028 Description of the Patients with Advanced Squamous NSCLC Treated in a Single Institution
Authors: Irene Torres, Joaquín Gimeno, Isabel Pajares, Ana Comin, Jorge Hernando, Pilar Felices, Ana Nuño, Esther Millastre, Ana Viñaras, Angel Artal Cortes
Journal: Journal of Thoracic Oncology (2017)
High Dose (5mg) Daily Folic Acid Supplement in Healthy Brazilian Volunteers Increases Mononuclear TNF-Î± Expression and Reduces NK Cell Number and Activity
Authors: Juliano Bertinato, Clovis Paniz, Maylla Rodrigues Lucena, Patrícia Mendonça da Silva Amorim, Guilherme Wataru Gomes, Maria Stella Figueiredo, Ralph Green, Elvira Maria Guerra Shinohara
Journal: Blood (2015)
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Authors: Giovanni Luca Gravina, Andrea Mancini, Francesco Marampon, Alessandro Colapietro, Simona Delle Monache, Roberta Sferra, Flora Vitale, Peter J. Richardson, Lee Patient, Stephen Burbidge, Claudio Festuccia
Journal: Journal of Hematology & Oncology (2017)

Glioblastoma recurrence after treatment with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is characterized by a highly infiltrative and malignant behavior that renders surgical excision and chemotherapy ineffective. It has been demonstrated that anti-VEGF/VEGFR therapies control the invasive phenotype and that relapse occurs through the increased activity of CXCR4. We therefore hypothesized that combining bevacizumab or sunitinib with the novel CXCR4 antagonist, PRX177561, would have superior antitumor activity. The effects of bevacizumab, sunitinib, and PRX177561 were tested alone or in combination in subcutaneous xenografts of U87MG, U251, and T98G cells as well as on intracranial xenografts of luciferase tagged U87MG cells injected in CD1-nu/nu mice. Animals were randomized to receive vehicle, bevacizumab (4 mg/kg iv every 4 days), sunitinib (40 mg/kg po qd), or PRX177561 (50 mg/kg po qd). The in vivo experiments demonstrated that bevacizumab and sunitinib increase the in vivo expression of CXCR4, SDF-1α, and TGFβ1. In addition, we demonstrate that the co-administration of the novel brain-penetrating CXCR4 antagonist, PRX177561, with bevacizumab or sunitinib inhibited tumor growth and reduced the inflammation. The combination of PRX177561 with bevacizumab resulted in a synergistic reduction of tumor growth with an increase of disease-free survival (DSF) and overall survival (OS), whereas the combination of PRX177561 with sunitinib showed a mild additive effect. The CXC4 antagonist PRX177561 may be a valid therapeutic complement to anti-angiogenic therapy, particularly when used in combination with VEGF/VEGFR inhibitors. Therefore, this compound deserves to be considered for future clinical evaluation.
P2.03a-050 Elevated Expression of CCP Genes is Associated with Absolute Chemotherapy Benefit in Early Stage Lung Adenocarcinoma Patients
Authors: Prasad Adusumilli, Raphael Bueno, Robert Cerfolio, David Harpole, Takashi Eguchi, Shaohua Lu, Corrine Gustafson, Sandra Calloway, Mary-Beth Joshi, Brent Evans, Elisha Hughes, Kraig Yager, Alison Sibley, Joshua Jones, Anne-Renee Hartman, Brian Allen
Journal: Journal of Thoracic Oncology (2017)
M1 Development of a ‘STOP-GO’ screening tool for streamlining assessment of common comorbidities in copd patients
Authors: SL Kennie, HK Lamplough, EH Baker, S McIvor
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> People with COPD admitted to hospital with exacerbations have multiple co-morbidities, impacting on survival, re-hospitalisation and health status<sup>1</sup>. Although commonly described, there is no consensus coordinating management of COPD and co-morbidities in time- and resource-limited healthcare. We developed a pragmatic ‘stop-go’ pre-screening tool to streamline co-morbidity assessment and determined its efficacy in predicting co-morbid diagnoses made <i>ad-hoc</i> in COPD patients in the year following hospitalisation. <h3>Methods</h3> Criteria were developed from NICE guidelines for twelve common COPD co-morbidities (Table). These indicated whether each condition was either not present or already diagnosed and treated (STOP – no further action required) or whether it could be present but undetected or could not be assessed (GO –further action required). Electronic records (all patients) and hospital notes (84 patients) were reviewed for COPD patients admitted with exacerbations 1/9/2014–31/12/14 who survived for the subsequent year. The ‘stop-go’ screening tool was completed from admission data. <i>Ad-hoc</i> identification of new co-morbidities, defined by physician-diagnosis or commencement of new medication, was noted over 1 year follow up. <h3>Results</h3> 120 patients (53% male, 47% female; age 73 ± 10 years) were included. The “stop-go “screening tool identified 7 ± 2 co-morbidities per patient requiring no action and 5 ± 2 co-morbidities (‘could be present’, 2 ± 1; ‘unable to assess’ 3 ± 3) where further action was required. Information from patient records was generally insufficient to screen for anxiety and depression and lacking for around one quarter of patients for atrial fibrillation, diabetes mellitus and cognitive impairment. During 1 year follow-up, patients developed 0.6 ± 0.9 (range 0–3) new diagnoses from the co-morbidities list. The ‘stop-go’ tool was most effective at predicting <i>ad hoc</i> diagnosis of hypertension, heart failure and osteoporosis (table) and less effective at predicting atrial fibrillation and ischaemic heart disease. <h3>Conclusions</h3> The ‘stop-go’ pre-screening tool has potential to cut down the number of co-morbidities that need to be assessed in time-limited consultations. This could be improved by inclusion of anxiety and depression scoring, routine ECG and HbA1c. It shows early promise in predicting <i>ad-hoc</i> diagnoses, but now needs to be tested prospectively towards improving systematic and cohesive care provision. <h3>Reference</h3> Public Health Reviews. 2011;<b>32</b>:451–474.
Hypercoagulability Linked to Breast Cancer Depends On the Stage and the Duration of the Tumor Evolution
Authors: Mourad Chaari, Grigoris T Gerotziafas, Lilia Ghorbal, Vassiliki Galea, Ines Ayadi, Patrick Van Dreden, Mariette Adam, Racem Bouzguenda, Mounir Frikha, Jamel Daoud, Choumous Kallel, Barry J Woodhams, Ismail Elalamy
Journal: Blood (2012)
P3.01-048 Cigarette Smoking is Associated with Epithelio-Mesenchymal Transition in Human Adenocarcinoma
Authors: Toshi Menju, Ryo Miyata, Shigeto Nishikawa, Koji Takahashi, Hiroyuki Cho, Shinya Neri, Takao Nakanishi, Masatsugu Hamaji, Hideki Motoyama, Kyoko Hijiya, Akihiro Aoyama, Toyofumi Chen-Yoshikawa, Toshihiko Sato, Makoto Sonobe, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date
Journal: Journal of Thoracic Oncology (2017)
Plasma oxypurinol as a measure of adherence in clinical trials
Authors: Lisa K Stamp, Tony Merriman, Christopher Frampton, Mei Zhang, Mary Wallace, Jeffrey N Miner, Nicola Dalbeth
Journal: Annals of the Rheumatic Diseases (2017)

Adherence to urate-lowering therapy (ULT) in people with gout is often poor. A recent systematic review revealed 10%–46% of people with gout adhere to treatment.1 Among chronic diseases, gout has particularly low adherence rates.2 Adherence in clinical trials of ULT is a particularly important issue, as the primary efficacy endpoint for most studies (including phase III studies that form the basis of regulatory approval) is the ability of the agent to reduce serum urate (SU). Pill count-based adherence ≥80% is frequently regarded as an appropriate cut-off for good adherence; however, this is an indirect measure. Measurement of drug concentration may be an improved measure of the adherence.3 The aim of this study was to establish the relationship between two different measures of adherence and SU endpoints in a clinical trial of allopurinol in gout.

Data, including demographics, SU, estimated glomerular filtration rate (eGFR), and plasma oxypurinol and allopurinol concentrations were available from a single study visit, and cumulative pill counts from the entire study period were available for 395 …
Hepcidin Suppression Relative to Iron Status in Patients with Chronic Hepatitis C.
Authors: Domenico Girelli, Michela Pasino, Julia Goodnough, Elizabeta Nemeth, Annalisa Castagna, Fabiana Busti, Natascia Campostrini, Nicola Martinelli, Maria Guido, Italo Vantini, Roberto Corrocher, Tomas Ganz, Giovanna Fattovich
Journal: Blood (2008)
MA15.01 Immunogram for Cancer-Immunity Cycle towards Personalized Immunotherapy of Lung Cancer
Authors: Takahiro Karasaki, Kazuhiro Nagayama, Hideki Kuwano, Jun-Ichi Nitadori, Masaaki Sato, Masaki Anraku, Akihiro Hosoi, Hirokazu Matsushita, Yasuyuki Morishita, Kosuke Kashiwabara, Masaki Takazawa, Osamu Ohara, Kazuhiro Kakimi, Jun Nakajima
Journal: Journal of Thoracic Oncology (2017)
A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289)
Authors: Thomas E. Witzig, Sumithra Mandrekar, Kristen Detweiler-Short, Martha Q Lacy, Kristina Laumann, Angela Dispenzieri, Suzanne R. Hayman, Shaji Kumar, Craig B. Reeder, Vivek Roy, John A Lust, Morie A Gertz, Philip R. Greipp, S. Vincent Rajkumar
Journal: Blood (2010)
P1.05-064 Global Practice Patterns of Multifocal Lung Cancer
Authors: Aaron Mansfield, Konstantinos Leventakos, Tobias Peikert, David Midthun, Julian Molina, Shanda Blackmon, Francis Nichols, Yolanda Garces, Christopher Hallemeier, Sarah Kratz, William Holland, Charles Thomas, John Mullon, Robert Shen, Stephen Cassivi, Randolph Marks, Marie Aubry, Alex Adjei, Ping Yang, Mark Allen, Eric Edell, Dennis Wigle
Journal: Journal of Thoracic Oncology (2017)
Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study
Authors: Allen Eng Juh Yeoh, Hany Ariffin, Ah Moy Tan, Thi Thu Ha Truong, Hai Peng Lin, Yiong Huak Chan, Shirley Kow Yin Kham, Thuan Chong Quah
Journal: Blood (2008)
P3.02c-058 In-Depth Molecular Characterization of T Cell Clonal Expansion Induced by Anti-PD1 Therapy in NSCLC
Authors: Sope Olugbile, Kazuma Kiyotani, Hiroyuki Inoue, Jae-Hyun Park, Phillip Hoffman, Livia Szeto, Jyoti Patel, Everett Vokes, Yusuke Nakamura
Journal: Journal of Thoracic Oncology (2017)